Healthy
Conditions
Brief summary
An open label randomized, single dose, two-way crossover bioequivalence study to determine the bioequivalence of Favipiravir from Flupirava 200 mg tablet (European Egyptian Pharmaceutical Industries, Egypt) versus Avigan 200 mg Tablets (Man. by Toyama Chemical Co., Ltd Japan) in Healthy Human Volunteers Under Fasting Condition.
Detailed description
Primary Pharmacokinetic Parameters: Cmax, AUC0→t and AUC0→∞ Secondary Pharmacokinetic Parameters: Ke, tmax and t1/2e. ANOVA using 5% significance level for transformed (with the 90% confidence intervals) and untransformed data of Cmax, AUC0→t and AUC0→∞ and for untransformed data of Ke, tmax and t1/2e. The confidence intervals of logarithmically transformed Test/Reference ratios for Cmax, AUC0→t and AUC0→∞ to be within 80.00-125.00%. A comprehensive final report will be issued upon the completion of the study.
Interventions
DRUGFlupirava
1 tablet contains 200 mg Favipiravir
DRUGAvigan
1 tablet contains 200 mg Favipiravir
Sponsors
European Egyptian Pharmaceutical Industries
Genuine Research Center, Egypt
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
OTHER
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 55 Years
Healthy volunteers
Yes
Inclusion criteria
* 1\. Healthy male or female, age 18 to 55 years, inclusive. 2. Body weight within 15% of normal range according to the accepted normal values for body mass index (BMI). 3\. Medical demographics without evidence of clinically significant deviation from normal medical condition. 4\. Results of clinical laboratory test are within the normal range or with a deviation that is not considered clinically significant by principal investigator. 5\. Subject does not have allergy to the drugs under investigation. 6. Females should be on a suitable birth control method.
Exclusion criteria
* 1\. Subjects with known allergy to the products tested. 2. Subjects whose values of BMI were outside the accepted normal ranges. 3. Female subjects who were pregnant or nursing. 4. Medical demographics with evidence of clinically significant deviation from normal medical condition. 5\. Results of laboratory tests which are clinically significant. 6. Acute infection within one week preceding first study drug administration. 7. History of drug or alcohol abuse. 8. Subject does not agree not to take any prescription or non-prescription drugs within two weeks before first study drug administration and until the end of the study. 9\. Subject is on a special diet (for example subject is vegetarian). 10. Subject does not agree not to consume any beverages or foods containing methyl-xanthenes e.g. caffeine (coffee, tea, cola, chocolate etc.) 48 hours prior to the study administration of either study period until donating the last sample in each respective period. 11\. Subject does not agree not to consume any beverages or foods containing grapefruit 7 days prior to first study drug administration until the end of the study. 12\. Subject has a history of severe diseases which have direct impact on the study. 13\. Participation in a bioequivalence study or in a clinical study within the last 6 weeks before first study drug administration. 14\. Subject intends to be hospitalized within 3 months after first study drug administration. 15\. Subjects who, through completion of this study, would have donated more than 500 ml of blood in 7 days, or 750 ml of blood in 30 days, 1000 ml in 90 days, 1250 ml in 120 days, 1500 ml in 180 days, 2000 ml in 270 days, 2500 ml of blood in 1 year.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Cmax | Up to 36 hours post dose in each treatment period | Maximal measured plasma concentration |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Time of the maximum plasma concentration (Tmax) | Up to 36 hours post dose in each treatment period | The amount of time that a drug is present at the maximum concentration in serum |
Countries
Egypt
Outcome results
None listed